Bridging the Gut–Brain Axis: Advanced Drug Delivery, Microbiome Modulation, and Translational Therapeutics

Dear Colleagues,

The gut–brain axis (GBA), a complex bidirectional communication network between the gut and the central nervous system (CNS), has garnered significant attention over the last decade due to its potential impact on both physiological and psychological health. Traditionally, the role of the gut was confined to the digestion and absorption of nutrients, but recent advances have revealed that the gut microbiota plays a crucial role in regulating mood, behavior, and neurological function. This discovery opens new avenues for pharmaceutical development, especially in the treatment of neurodegenerative diseases, mental health disorders, and gastrointestinal diseases. The intersection of the gut–brain axis and pharmaceutics is poised to revolutionize the way we approach therapeutic interventions, creating opportunities for novel drug delivery systems, microbiome-targeted therapies, and more personalized treatment paradigms.

Rationale:

The relationship between the gut microbiome and the brain offers a promising frontier for pharmaceutical research. However, despite significant strides in understanding the molecular mechanisms of the gut–brain axis, there remains a gap in translating this knowledge into effective treatments. The pharmaceutical industry is beginning to recognize the potential of microbiome-based therapies, but much remains to be discovered, particularly in terms of developing reliable and scalable treatment modalities. Additionally, there is a need for further exploration of drug formulations and delivery mechanisms that can target both the gut and the brain efficiently.

This Special Issue seeks to consolidate cutting-edge research/reviews on the gut–brain axis and its implications for pharmaceutics. It will highlight novel drug delivery systems, microbiome modulation strategies, and emerging therapeutic targets that can bridge the gap between preclinical research and clinical application. By presenting a multidisciplinary perspective, this issue will appeal to scientists in pharmaceutical sciences, microbiology, neuroscience, and clinical research, ultimately fostering collaboration and accelerating the translation of research into therapeutic practices.

Topics of Interest:

We invite contributions that explore, but are not limited to, the following areas:

1. Potential Therapeutic Microbiome–Gut–Brain Interactions
2. Pharmacological Modulation of the Gut–Brain Axis:

Emerging microbiome-based therapies for neurological and psychiatric disorders.

Drug formulations aimed at modulating gut microbiota to improve brain function.

The role of antibiotics, antimicrobials, and other pharmaceuticals in shaping the gut microbiome and their neurological consequences.

3. Novel Drug Delivery Systems Targeting the Gut–Brain Axis:

Advances in drug delivery technologies designed to cross the blood–brain barrier (BBB) and target the gut microbiota.

Nanomedicine and nanoformulations for gut–brain communication.

Design and optimization of oral drug delivery systems that can address both gut and CNS disorders.

4. Clinical Applications and Trials:

Review of ongoing research exploring the gut–brain axis in drug development.

Challenges and opportunities in translating gut–brain axis research to clinical settings.

Regulatory and safety considerations for microbiome-based therapeutics.

Impact:

The goal of this Special Issue is to provide a comprehensive overview of the state-of-the-art research in the field of the gut–brain axis and pharmaceutics. It aims to address several key challenges:

1. Bridging the gap between basic research and clinical application.
2. Introducing innovative drug delivery systems that consider both the microbiome and neurological health.
3. Stimulating the development of novel therapies targeting the gut–brain axis for conditions that are currently difficult to treat, such as depression, Alzheimer's, and gut-related disorders.

This issue will serve as a valuable resource for pharmaceutical scientists, clinicians, and researchers, fostering a deeper understanding of how microbiome modulation can influence drug efficacy and therapeutic outcomes.

Conclusion:

As research into the gut–brain axis continues to evolve, the need for a unified platform to showcase cutting-edge developments becomes increasingly urgent. This Special Issue will provide a timely and comprehensive exploration of how pharmaceutical innovations can be tailored to harness the potential of the gut–brain axis, ultimately paving the way for new therapeutic strategies in neurology and psychiatry. By promoting collaboration across multiple scientific disciplines, this issue will contribute significantly to advancing the field of pharmaceutical sciences and improving patient outcomes.

Dr. Arik Dahan
Dr. Sigal Fleisher-Berkovich
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gut–brain axis
• microbiome–gut–brain interactions
• drug delivery systems
• nanomedicine